Congress Coverage: ASH 2020 – Focus on Leukemia

Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia.

December 8, 2020

Faculty Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Faculty Members

Naval Daver, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Eunice Wang, MD
Roswell Park Comprehensive Cancer Center, New York, NY, USA

Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL, USA

Aaron Logan, MD, PhD
UCSF Health, San Francisco, CA, USA

Josep-Maria Ribera, MD, PhD
Hospital Universitari Germans Trias i Pujol, Barcelona, Spain

Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York City, NY, USA

Amir Fathi, MD
Massachusetts General Hospital, Boston, MA, USA

Sample Report

Start discovering the insights

View Report


  • Clinical experts from across the world discussed global perspectives on current treatment strategies and emerging therapies in leukemia derived from ASH 2020 data
  • The goal of the expert panel was to critique and debate new evidence in leukemia and gain strategic insight into the most impactful abstracts from the ASH meeting with respect to shaping current research directions and/or changing the scope of practical clinical care

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.